论文部分内容阅读
目的:探索仿制药/原研药的比价(PR)与仿制药的生产厂家数量(QM)的关系。方法:采用上海医院购药信息系统(HPDIS)的数据,筛选出仿制药及其对应的原研药,计算两者有效成份最小计量单位的PR,同时,统计每个仿制药的QM,并对PR与QM进行相关和回归分析。结果:PR的均值为0.54±0.26,中位数为0.57;QM的均值为3.07±2.46,中位数为2.00;两者的相关系数为-0.36,线性回归方程为PR=-0.04QM+0.66。结论:本研究结果可以为有关管理部门合理控制PR和QM提供参考。
OBJECTIVE: To explore the relationship between generic price (PR) and generic drug manufacturer (QM). Methods: According to the data of Shanghai Pharmaceuticals Information System (HPDIS), the generic drugs and their corresponding original drugs were screened out to calculate the PR of the minimum effective units of the two active ingredients. At the same time, the QM of each generic drug was counted, Correlation and regression analysis with QM. Results: The mean of PR was 0.54 ± 0.26 and the median was 0.57. The mean of QM was 3.07 ± 2.46 and the median was 2.00. The correlation coefficient between the two was -0.36. The linear regression equation was PR = -0.04QM + 0.66 . Conclusion: The results of this study can provide reference for relevant management departments to control PR and QM properly.